Deformation Imaging by Strain in Chronic Heart Failure Over Sacubitril‐Valsartan: A Multicenter Echocardiographic Registry

Bibliographic Details
Title: Deformation Imaging by Strain in Chronic Heart Failure Over Sacubitril‐Valsartan: A Multicenter Echocardiographic Registry
Authors: Giulia Elena Mandoli, Maria Concetta Pastore, Alberto Giannoni, Giovanni Benfari, Frank Lloyd Dini, Gianmarco Rosa, Nicola Riccardo Pugliese, Claudia Taddei, Michele Correale, Natale Daniele Brunetti, Pietro Mazzeo, Erberto Carluccio, Anna Mengoni, Andrea Igoren Guaricci, Laura Piscitelli, Rodolfo Citro, Michele Ciccarelli, Giuseppina Novo, Egle Corrado, Annalisa Pasquini, Valentina Loria, Giuseppe De Carli, Anna Degiovanni, Giuseppe Patti, Ciro Santoro, Luca Moderato, Mariantonietta Cicoira, Marco Canepa, Alessandro Malagoli, Michele Emdin, Matteo Cameli
Source: ESC Heart Failure, Vol 10, Iss 2, Pp 846-857 (2023)
Publisher Information: Wiley, 2023.
Publication Year: 2023
Collection: LCC:Diseases of the circulatory (Cardiovascular) system
Subject Terms: Heart failure, Sacubitril/valsartan, Speckle tracking, Echocardiography, Remodelling, Imaging, Diseases of the circulatory (Cardiovascular) system, RC666-701
More Details: Abstract Aims Sacubitril/valsartan has changed the treatment of heart failure with reduced ejection fraction (HFrEF), due to the positive effects on morbidity and mortality, partly mediated by left ventricular (LV) reverse remodelling (LVRR). The aim of this multicenter study was to identify echocardiographic predictors of LVRR after sacubitril/valsartan administration. Methods and results Patients with HFrEF requiring therapy with sacubitril/valsartan from 13 Italian centres were included. Echocardiographic parameters including LV global longitudinal strain (GLS) and global peak atrial longitudinal strain by speckle tracking echocardiography were measured to find the predictors of LVRR [= LV end‐systolic volume reduction ≥10% and ejection fraction (LVEF) improvement ≥10% at follow‐up] at 6 month follow‐up as the primary endpoint. Changes in symptoms [New York Heart Association (NYHA) class] and neurohormonal activations [N‐terminal pro‐brain natriuretic peptide (NT‐proBNP)] were also evaluated as secondary endpoints; 341 patients (excluding patients with poor acoustic windows and missing data) were analysed (mean age: 65 ± 10 years; 18% female, median LVEF 30% [inter‐quartile range: 25−34]). At 6 month follow‐up, 82 (24%) patients showed early complete response (LVRR and LVEF ≥ 35%), 55 (16%) early incomplete response (LVRR and LVEF
Document Type: article
File Description: electronic resource
Language: English
ISSN: 2055-5822
Relation: https://doaj.org/toc/2055-5822
DOI: 10.1002/ehf2.14155
Access URL: https://doaj.org/article/c8131d0985ed4f18b6787e51d622d7b1
Accession Number: edsdoj.8131d0985ed4f18b6787e51d622d7b1
Database: Directory of Open Access Journals
More Details
ISSN:20555822
DOI:10.1002/ehf2.14155
Published in:ESC Heart Failure
Language:English